Skip to main content
. 2020 Jun 23;12(6):1661. doi: 10.3390/cancers12061661

Figure 6.

Figure 6

N-Acetyl Cysteine (NAC), a ROS scavenger, can re-sensitize BRAF pathway inhibitor-resistant melanoma cells. (A) WM-115 TDR and WM-983 TDR cells (30,000 cells/well) were plated in triplicate and treated with DMSO, 5 mM N-Acetyl Cysteine (NAC), and/or 2.4 μM dabrafenib and 500 nM trametinib, as indicated. (B) WM-115 TDR and WM-983 TDR cells were plated in triplicate in 96 well plates and treated for 72 h with DMSO, 5 mM NAC, and/or 2.4 μM dabrafenib and 500 nM trametinib, as indicated. * p < 0.05 versus DMSO control. Statistical analysis by one way ANOVA.